Preferred Label : tralokinumab;
MeSH note : a potent and selective IL-13-neutralizing IgG4 mAb;
CISMeF synonym : CAT-354;
Is substance : O;
UNII : GK1LYB375A;
Origin ID : C574065;
UMLS CUI : C3658667;
ATC code(s)
Currated CISMeF NLP mapping
MeSH indexing information
MeSH term(s) associated for indexing
Record concept(s)
Semantic type(s)
UMLS correspondences (same concept)
Validated automatic mappings to BTNT
https://www.has-sante.fr/jcms/p_3498562/fr/adtralza-tralokinumab-dermatite-atopique-chez-l-adulte-et-l-adolescent-a-partir-de-12-ans
2024
false
false
false
France
tralokinumab
injections, subcutaneous
adolescent
adult
dermatitis, atopic
Adult atopic dermatitis (disorder)
evaluation of the transparency committee
tralokinumab
---
https://www.has-sante.fr/jcms/p_3539087/fr/adtralza-tralokinumab-maladies-inflammatoires-chroniques
2024
false
false
false
France
biological therapy
drug prescriptions
tralokinumab
evaluation of the transparency committee
administration, cutaneous
tralokinumab
---
https://www.has-sante.fr/jcms/p_3460130/fr/adtralza-tralokinumab-dermatite-atopique-chez-l-adolescent-a-partir-de-12-ans
2023
false
false
false
France
treatment outcome
insurance, health, reimbursement
tralokinumab
injections, subcutaneous
evaluation of the transparency committee
tralokinumab
dermatitis, atopic
adolescent
---
https://www.has-sante.fr/jcms/p_3382739/fr/adtralza-tralokinumab
2022
false
false
false
France
treatment outcome
insurance, health, reimbursement
tralokinumab
dermatitis, atopic
adult
Adult atopic dermatitis (disorder)
injections, subcutaneous
evaluation of the transparency committee
tralokinumab
---
https://www.has-sante.fr/jcms/p_3297690/fr/adtralza-tralokinumab-dermatite-atopique
2021
false
false
false
France
dermatitis, atopic
tralokinumab
tralokinumab
treatment outcome
adult
injections, subcutaneous
evaluation of the transparency committee
---
https://www.ema.europa.eu/en/medicines/human/EPAR/adtralza
2021
false
false
false
Netherlands
French
English
treatment outcome
syndication feed
summary of product characteristics
package leaflet
drug evaluation
tralokinumab
tralokinumab
drug approval
europe
tralokinumab
adult
dermatitis, atopic
injections, subcutaneous
Interleukin-13
drug monitoring
aged
drug interactions
pregnancy
breast feeding
drug evaluation, preclinical
antibodies, monoclonal
antibodies, monoclonal
---
https://ansm.sante.fr/tableau-atu-rtu/adtralza-150-mg-solution-injectable-en-seringue-preremplie
2021
false
false
false
France
French
tralokinumab
tralokinumab
guidelines for drug use
summary of product characteristics
package leaflet
adult
dermatitis, atopic
antibodies, monoclonal
antibodies, monoclonal
---
https://www.cadth.ca/fr/tralokinumab
2021
false
false
false
Canada
French
insurance, health, reimbursement
dermatitis, atopic
drug information
adult
tralokinumab
antibodies, monoclonal
---
https://www.has-sante.fr/jcms/p_3305309/fr/adtralza-150-mg-tralokinumab
2021
false
false
false
France
evaluation of the transparency committee
tralokinumab
tralokinumab
registries
---